Elritercept

Product

Last mentioned: Mar 4, 2026

Timeline

  1. FY 2025 Earnings

    Released full-year financial results and updated 2026 clinical guidance.

  2. Anticipated Data

    Expected top-line data readouts for multiple Phase 2 programs.

  3. Cibotercept Progress

    Initiated additional cohorts in PAH studies to evaluate dose-response.

  4. Trial Expansion

    Keros expanded the TROPOS trial to include broader MDS patient populations.

Stories mentioning Elritercept 1

market-trends Neutral

Keros Therapeutics Advances TGF-β Pipeline Amid Q4 2025 Financial Results

Keros Therapeutics reported its full-year 2025 results, highlighting significant clinical progress in its TGF-β protein superfamily pipeline for hematologic and cardiovascular disorders. The company maintains a robust cash position to fund pivotal trials for elritercept and cibotercept through key upcoming data readouts in 2026.

2 sources